Rabicid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rabicid

Property Description
Active Ingredient Rabeprazole sodium
Form Enteric-coated tablet
Pharmacological Class Proton pump inhibitor (PPI)
Common Type Anti-secretory agent
Origin Synthetic drug

What Type of Medicine is Rabicid?

Rabicid is a specific trade name for a medicine containing the active ingredient Rabeprazole sodium, which functions as a potent gastric acid suppressor. It belongs to the Proton pump inhibitor (PPI) pharmacological class, a group of anti-secretory agents that act directly on the acid-producing cells in the stomach. This classification indicates the drug is used to achieve substantial, long-lasting reduction in stomach acid. Rabicid is categorized as a Prescription-only medicine, signifying its use in scenarios where sustained acid control is required. The PPI group is clinically recognized for its reliable efficacy, distinct from older acid blockers such as H₂-receptor antagonists, by being designed to more completely suppress acid production.

Composition and Physical Form of Rabeprazole

The active component, Rabeprazole, is a synthetic drug and is chemically characterized as a substituted benzimidazole derivative. The medicine is specifically formulated for oral administration as an enteric-coated tablet. This specialized dosage form is critical because the Rabeprazole sodium active substance is inherently unstable in the stomach's highly acidic environment. The coating ensures the drug passes safely to the intestine for absorption, allowing it to reach the target cells effectively.

What is the General Purpose of Rabicid?

The general purpose of Rabicid is to provide therapeutic relief from symptoms linked to excessive acid production. This consistent reduction in gastric acid secretion is the drug's primary function, creating a less corrosive environment in the upper gastrointestinal tract and serving as the basis for its overall therapeutic benefit as an anti-secretory agent. For instance, it provides support in managing symptoms associated with frequent heartburn.

Regulatory References

  1. Rabeprazole: MedlinePlus Drug Information
  2. FDA Label: RABEPRAZOLE SODIUM Tablet

What side effects are possible with Rabicid?

Possible Side Effects and Safety Information

The official safety information for Rabicid (Rabeprazole sodium) categorizes possible adverse reactions primarily by frequency, as established in regulatory documents like the Summary of Product Characteristics (SmPC) and FDA labeling. The majority of reactions observed in clinical use are generally mild to moderate.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions
Common (ge 1% to <10%) Headache, diarrhea, nausea, abdominal pain, flatulence, vomiting, constipation, and asthenia (weakness).
Uncommon (ge 0.1% to <1%) Dizziness, somnolence (drowsiness), rash, myalgia (muscle pain), arthralgia (joint pain), and pyrexia (fever).
Rare (ge 0.01% to <0.1%) Hepatitis, jaundice, hepatic encephalopathy (in pre-existing disease), and blood disorders such as leukopenia.

Clinically Significant and Duration-Related Safety Notes

Several serious adverse reactions have been documented, including Acute Tubulointerstitial Nephritis (ATIN), which is an acute kidney inflammation, and severe skin reactions like Stevens-Johnson Syndrome (SJS). These are typically reported through post-marketing surveillance.

Safety concerns explicitly linked to long-term use (generally one year or longer) include an officially noted increase in the risk of bone fracture (hip, wrist, or spine) and the development of fundic gland polyps. Furthermore, hypomagnesemia (low blood magnesium levels) and Vitamin B-12 deficiency are conditions associated with prolonged administration.

Special Safety Constraints

Regulatory documents emphasize that a response to treatment does not exclude the possibility of an underlying gastric or esophageal malignancy, requiring this to be ruled out prior to therapy. Caution is also advised when administering the medicine to patients with severe hepatic impairment.

Overdose and Emergency Response

The official regulatory documentation on Rabeprazole sodium overdosage indicates that clinical experience is limited. Overdoses reported in studies, including high exposures exceeding standard therapeutic limits, have been associated with minimal or no acute clinical signs or symptoms. When effects are observed, they are generally reversible and correlate with the known adverse event profile of the drug. A key physiological constraint noted in labeling is that Rabeprazole sodium is extensively protein bound and therefore not readily dialyzable, which informs the strategy for supportive care.

No specific antidote is known for Rabeprazole sodium overdose, meaning management must be strictly symptomatic and supportive treatment. This standard requires meticulous monitoring of the patient's vital signs, blood gases, and serum electrolytes. Procedures for supportive treatment also include protecting the patient's airway and actively supporting ventilation and perfusion. Official guidance directs users to seek emergency medical attention immediately in the event of any suspected overdosage. Furthermore, immediate contact with emergency services is mandated if critical symptoms occur, such as collapse, seizure, or severe trouble breathing.

Therapeutic Uses of Rabicid

Rabicid's Main Uses and Therapeutic Benefits

Rabicid is a medication that supports patients in managing a range of conditions where the main issue is symptoms related to heightened physiological activity or systemic imbalance. It is generally used for conditions involving episodic or fluctuating manifestations, helping patients with short-term symptomatic assistance.

The primary role of this medication is applied across domains where additional symptomatic support is needed, particularly for symptoms associated with gastric discomfort and episodic manifestations. This therapeutic approach contributes to easing the overall symptom load and improved day-to-day comfort during symptomatic periods.

The medication is commonly used across conditions presenting with acute episodes where multiple symptoms occur together, leading to temporary functional strain. It helps patients cope more steadily with symptom fluctuations, and this medication may assist with managing symptoms that interfere with daily functioning, such as difficulty swallowing and persistent cough.


Quick Fact

Quick Fact: Supports in managing Symptoms of Heightened Physiological Activity

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Rabicid?

Eligibility for Rabicid (rabeprazole sodium) is strictly defined by government regulatory documents, focusing on patient age, physiological state, and pre-existing conditions.

Contraindicated Populations

Rabicid must not be used by individuals with a known hypersensitivity to rabeprazole sodium, to any component of the formulation, or to any other substituted benzimidazoles (the PPI class). Use is also contraindicated for patients concurrently taking rilpivirine-containing products.

Age-Related Eligibility

Age Group Eligibility Status (Regulatory)
Adults (18+ Years) Established Use for approved indications.
Adolescents (12–17 Years) Established Use for symptomatic GERD.
Children (Under 1 Year) Not recommended for use.

Restrictions and Cautions

Pregnancy and Lactation: In many regions, use is contraindicated due to unestablished safety. Pre-treatment requirements dictate that the possibility of gastric malignancy must be excluded before initiating therapy. Caution is advised for patients with severe hepatic dysfunction due to limited clinical data. For patients with renal impairment or mild to moderate hepatic impairment, no dosage adjustment is necessary.

What should I know about interactions with other medicines?

Rabicid's official interaction profile is primarily defined by its effect on gastric pH and documented metabolic pathways, resulting in specific exposure modifications and mandatory restrictions on co-administration.

Interactions Affecting Drug Exposure

Rabicid inhibits gastric acid secretion, which leads to documented pharmacokinetic interactions with substances whose absorption is pH-dependent. This effect causes decreased exposure for medicinal products requiring an acidic environment, including certain antiretrovirals (Atazanavir, Nelfinavir) and azole antifungals (Ketoconazole, Itraconazole). Conversely, this pH elevation can result in an increase in exposure for other drugs, such as Digoxin, where plasma levels ( C max and AUC) are documented to rise, necessitating monitoring. Concomitant use with Warfarin has also been associated with reports of increased International Normalized Ratio (INR) and prothrombin time, also requiring monitoring.

Restrictions and Timing Rules

Interaction Classification Interacting Substance Official Constraint
Contraindicated Rilpivirine-containing products Prohibited due to risk of reduced efficacy.
Timing Separation Atazanavir Must be administered approx 12 hours apart.

The exposure of Rabicid itself may be decreased by strong inducers of CYP2C19 and CYP3A4. Long-term daily use is also documented to be associated with malabsorption of Cyanocobalamin (Vitamin B-12).

Connection to the overall interaction profile: Regulatory documents define the Rabicid interaction profile predominantly through its action as an anti-secretory agent, resulting in pH-Dependent Drug Interactions that either decrease or increase the exposure of co-administered medicines. This profile is structurally completed by specific Contraindications and required Monitoring for certain substances, establishing the official constraints on co-administration.

Mechanism of Action

Rabicid, containing the active molecule rabeprazole, is a substituted benzimidazole compound and a member of the proton-pump inhibitor class. The inactive parent molecule, a prodrug, is absorbed and selectively accumulates within the acidic secretory canaliculi of the gastric parietal cells . This low pH environment triggers the compound's chemical transformation via protonation into its active metabolite, an unstable sulfenamide or sulfenic acid. The active sulfenamide metabolite then functions as an irreversible inhibitor by forming covalent disulfide bonds with specific cysteine residues exposed on the extracellular surface of the H^+/ K^+-ATPase enzyme. This H^+/ K^+-ATPase, also known as the gastric proton pump, is the terminal enzymatic step in acid secretion. The covalent modification fundamentally blocks the enzyme's function, preventing the exchange of intraluminal K^+ for intracellular H^+ ions. This inhibition of H^+ transport into the gastric lumen leads to a sustained, dose-dependent decrease in the concentration of hydrochloric acid secreted into the stomach.

Dosage and Administration Information

How to Use Rabicid — Official Administration Guidelines

Rabicid (rabeprazole sodium) is administered orally and must be taken exactly as prescribed, with specific instructions varying based on the condition being treated and the patient's age. The official instructions define the precise administrative rules that govern its correct use.


Administration Method and Preparation

  • Delayed-Release Tablets: The tablets must be swallowed whole and should not be crushed, chewed, or split. Taking the tablet whole ensures the proper delayed release of the medicine.
  • Delayed-Release Capsules (Sprinkle): This form, often used for pediatric patients, must be opened, and the granules are to be sprinkled onto a spoonful of soft food (e.g., applesauce) or into a small amount of liquid. The granules must not be chewed or crushed. The mixture must be consumed within 15 minutes and should not be stored for later use.

Dosing and Timing

Condition Dose and Frequency Timing in Relation to Meals Age Group
Healing Duodenal Ulcers 20 mg once daily After the morning meal Adults
H. pylori Eradication 20 mg twice daily With morning and evening meals Adults
GERD (Adults/Adolescents) 20 mg once daily With or without food 12 years
GERD (Pediatric) 5 mg or 10 mg once daily 30 minutes before a meal 1–11 years

Missed Dose Instructions

If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should resume their regular dosing schedule. Do not take two doses at the same time to make up for a missed dose.

This protocol ensures the medication's efficacy by regulating the route, timing, and preparation steps, which are crucial for the integrity of the delayed-release formulation.

Recent Clinical Evidence

Recent Clinical Evidence for Rabicid (Rabeprazole)

Rabicid is a brand name for rabeprazole, a medication belonging to the proton pump inhibitor (PPI) class. Clinical research focuses on its utility in reducing gastric acid secretion and its effectiveness across various acid-related gastrointestinal conditions.


Efficacy in Gastroesophageal Reflux Disease (GERD)

Clinical trials have investigated rabeprazole's use for both the short-term healing of erosive or ulcerative GERD and the long-term maintenance of this healing. Studies indicate that rabeprazole can effectively suppress stomach acid, which supports the healing of esophageal erosions caused by acid reflux. In comparative trials, rabeprazole has shown comparable healing rates for erosive esophagitis to those of other PPIs at standard doses, typically within eight weeks.

Role in H. pylori Eradication

Rabeprazole is a component of several combination therapies designed to eradicate the bacterium Helicobacter pylori, which is a key contributor to peptic ulcer disease. Clinical evidence suggests that using rabeprazole in conjunction with appropriate antibiotics achieves eradication rates similar to other standard PPI-based regimens, helping to reduce the recurrence of duodenal and gastric ulcers.

Use in Peptic Ulcer Prevention

Long-term clinical investigations have explored rabeprazole's role in patients who require continued therapy with low-dose aspirin (LDA) for cardiovascular health. Studies indicate that sustained rabeprazole use may help in preventing the recurrence of peptic ulcers in individuals with a history of such ulcers who must continue LDA therapy. Evidence suggests this benefit may be achieved across different low doses of the medication.

Frequently Asked Questions (FAQ)

Common questions about Rabicid (FAQ)

Q: Is Rabicid the same as rabeprazole, or is it a combination medicine?

A: Rabicid is a brand name used for the active ingredient rabeprazole sodium. It is a single-ingredient medication belonging to the Proton Pump Inhibitor (PPI) class. While Rabicid itself is not a combination medicine, other products that combine rabeprazole with a different active drug may be available under alternative brand names.


Q: How long does it typically take for Rabicid to start providing symptom relief?

A: Regulatory data indicates the active ingredient begins its acid-suppressing action, known as the antisecretory effect, within about one hour after the first oral dose. However, the more significant effects on stomach and esophageal acidity are usually observed after about seven days of consistent treatment.


Q: Can Rabicid cause headaches or dizziness, and is this common?

A: Headaches and dizziness are listed in regulatory documents as possible adverse reactions. Headache is classified as a common side effect based on official documentation. Dizziness, in contrast, is classified as uncommon.


Q: Can Rabicid be taken at the same time as an H2 blocker like Pepcid?

A: Regulatory documents do not detail specific co-administration guidelines for taking PPIs and H2-blockers simultaneously. Rabicid's mechanism of action is distinct from H2-blockers, which are mentioned in official information as separate drug classes.


Q: What symptoms indicate a possible serious side effect like low magnesium (hypomagnesemia) from Rabicid?

A: Prolonged use of this medication can be associated with low blood magnesium levels (hypomagnesaemia). Serious manifestations of this condition may include fatigue, tetany (muscle spasms), delirium, convulsions, dizziness, and ventricular arrhythmia (irregular heartbeat). These symptoms are listed as signs of potentially serious conditions.


Q: Is Rabicid used in combination with antibiotics for H. pylori infection?

A: Yes. Official guidelines state that Rabicid (rabeprazole) is used as part of a three-drug regimen for the eradication of the bacterium H. pylori. This treatment typically combines rabeprazole with the antibiotics amoxicillin and clarithromycin.


Q: Is there any research suggesting Rabicid use is linked to kidney issues?

A: Regulatory information indicates that Acute Tubulointerstitial Nephritis (ATIN), which is a type of acute kidney inflammation, has been observed with rabeprazole and other drugs in the PPI class. This adverse reaction may occur during therapy.


Q: Why is Rabicid sometimes not recommended for children?

A: According to regulatory sources, Rabicid is not recommended for use in children under 1 year of age. This restriction exists because the safety and effectiveness of the medication have not been established in children under 1 year of age.


Q: What is Zollinger-Ellison syndrome, and how does Rabicid help treat it?

A: Zollinger-Ellison Syndrome (ZES) is a rare condition that causes the body to produce excessive amounts of stomach acid. Rabicid is officially indicated for the long-term treatment of ZES and other similar conditions characterized by this pathological high acid secretion.


Q: Can Rabicid affect the results of certain medical tests?

A: Taking this medication can lead to artificially increased levels of a substance called chromogranin A ( CgA) in the blood. These altered CgA levels can potentially interfere with the diagnostic results for neuroendocrine tumors. Official product information mentions that temporary discontinuation of the medicine is sometimes necessary prior to such testing.


Q: Is it common to feel more tired or weak when starting Rabicid?

A: The adverse reactions profile lists asthenia (a feeling of weakness or lack of energy) as a common side effect. Somnolence (drowsiness) is listed as an uncommon side effect. This information is intended to clarify potential expectations based on official regulatory data.


Q: Does Rabicid interact with common medications for anxiety or depression?

A: Rabicid is metabolized by specific liver enzymes ( CYP2C19 and CYP3A4) that are also involved in processing many other medications, including certain anxiety and depression drugs. Official labeling recommends that monitoring may be necessary when Rabicid is taken alongside drugs that are highly reliant on these enzyme systems.


Q: What is the difference between the 'DSR' formulation and regular Rabicid?

A: Rabicid contains rabeprazole alone. Formulations labeled with 'DSR,' such as Rabepraz-DSR, are generally combination medicines that pair rabeprazole with a second active drug, most commonly domperidone. Domperidone is used to help increase movement through the digestive tract.


Q: Does taking Rabicid make you more sensitive to the sun?

A: Regulatory information for PPIs, including rabeprazole, mentions an association with rare cases of the skin condition Subacute Cutaneous Lupus Erythematosus ( SCLE). The skin lesions associated with this condition most often appear in areas that are exposed to the sun.


Q: What is the maximum recommended duration for short-term use of Rabicid?

A: The recommended duration for short-term use varies depending on the medical condition being addressed. Official regulatory documents define different time frames based on the condition.


Q: Are there different strengths of Rabicid available, like 10mg or 20mg?

A: Yes. According to the official drug label, rabeprazole is manufactured and available as delayed-release tablets in strengths that include both 10 mg and 20 mg.


Q: What are the signs of a severe allergic reaction to Rabicid that warrant immediate attention?

A: Signs of a serious allergic reaction, known as hypersensitivity, may include difficulty breathing ( bronchospasm), significant swelling of the face, lips, or tongue ( angioedema), hives ( urticaria), or severe whole-body reactions like anaphylaxis. These are listed in post-marketing surveillance.


Q: Can Rabicid interact with supplements like St. John's Wort?

A: Rabicid is processed by certain liver enzymes. St. John's Wort is known to increase the activity of these same enzymes. This enzyme induction can decrease the amount of Rabicid in the body, which may affect the concentration of the medicine.


Q: Is it possible to develop a rash or skin reactions while on Rabicid?

A: Yes, it is possible. A rash is listed in the regulatory documents as an uncommon side effect. Additionally, much rarer but more severe skin reactions, such as Stevens-Johnson Syndrome ( SJS) and Toxic Epidermal Necrolysis ( TEN), have been reported in post-marketing surveillance.


Q: Does Rabicid need to be stored in a special way?

A: Official storage guidelines require that the medication be kept in its original packaging and stored in a cool, dry place. Specifically, it must be stored below 25 C and be protected from moisture and heat to maintain its stability.


Q: Is Rabicid commonly prescribed for non-acid-related stomach issues?

A: No. The official, FDA-approved indications for Rabicid (rabeprazole) are all specific to conditions caused by excessive gastric acid secretion. These include healing conditions like ulcers and Erosive GERD.


Q: Are there reported cases of muscle cramps or spasms related to Rabicid use?

A: Myalgia (muscle pain) is listed as an uncommon adverse reaction. Furthermore, in cases of severe hypomagnesaemia (low magnesium), which is associated with long-term PPI use, symptoms can include tetany (muscle spasms) and convulsions.

How should Rabicid be stored and disposed of?

How to Store and Dispose of Rabicid?

This section outlines the official requirements for storing and disposing of this medicine, based on government regulatory labeling.

Official Storage Requirements

  • Temperature and Environment: Store the medicine in a cool, dry place and below 25 C. The product must be protected from direct sunlight, moisture, and heat.
  • Packaging Integrity: Keep the medicine in the container or pack it came in, and ensure it is tightly closed.
  • Handling: The gastro-resistant tablets/capsules should be swallowed whole and must not be chewed or crushed. Do not use medicine that is expired or damaged.

Safety and Disposal Rules

  • Safety: The medicine must be kept out of the reach of children and out of the reach of pets at all times.
  • Disposal: Dispose of any unused or expired medicine properly. It is required to discard the medicine in a way that prevents consumption by people or pets. Do not flush it in the toilet or throw it into the drain to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rabicid found in:

A-Z Index: